Hepatic veno-occlusive disease
| Hepatic veno-occlusive disease | |
|---|---|
| Classification and external resources | |
| Specialty | gastroenterology |
| ICD-10 | K76.5 |
| OMIM | 235550 |
| DiseasesDB | 34365 |
| eMedicine | ped/2396 |
| MeSH | D006504 |
| GeneReviews | |
Hepatic veno-occlusive disease or veno-occlusive disease (VOD) is a condition in which some of the small veins in the liver are obstructed. It is a complication of high-dose chemotherapy given before a bone marrow transplant (BMT) and is marked by weight gain due to fluid retention, increased liver size, and raised levels of bilirubin in the blood. The name sinusoidal obstruction syndrome is now preferred if VOD happens as a result of chemotherapy or bone marrow transplantation.
Apart from chemotherapy, VOD may also occur after ingestion of certain plant alkaloids such as pyrrolizidine alkaloids (in some herbal teas), and has been described as part of a rare hereditary disease called hepatic venoocclusive disease with immunodeficiency (which results from mutations in the gene coding for a protein called SP110).
Features of VOD include weight gain, tender hepatomegaly, ascites, and jaundice; it often is associated with renal failure.
In the BMT setting, VOD is felt to be due to injury to the hepatic venous endothelium from the conditioning regimen.
Toxic agents causing veno-occlusive disease include plants as well as the medication cyclophosphamide.
Hepatic doppler ultrasound is typically utilized to confirm or suggest the diagnosis. Most common findings on liver doppler ultrasound include increased phasicity of portal veins with eventual development of portal flow reversal. The liver is usually enlarged but maintained normal echogenicity. A liver biopsy is required for a definitive diagnosis.
Treatment for VOD is primarily supportive. In the BMT setting, defibrotide is an investigational treatment that may be promising. Defibrotide is a polydeoxyribonucleotide isolated from pig intestine. Although its mechanism of action in VOD is unclear, the drug is believed to have antithrombotic properties. In August 2009, Gentium S.p.A., which sponsored the phase 3 clinical trial (pivotal) of defibrotide in hepatic VOD, announced disappointing results. Further clinical development of defibrotide for this indication is uncertain.
...
Wikipedia